Upadacitinib

In this Healio video, Aline Charabaty, MD clinical director of the Inflammatory Bowel Disease Center at Johns Hopkins, Sibley Memorial Hospital, discusses the underlying causes of ulcerative colitis.

In this Healio video, Aline Charabaty, MD clinical director of the Inflammatory Bowel Disease Center at Johns Hopkins, Sibley Memorial Hospital, discusses the underlying causes of ulcerative colitis.

In this Healio video, Aline Charabaty, MD clinical director of the Inflammatory Bowel Disease Center at Johns Hopkins, Sibley Memorial Hospital, discusses the underlying causes of ulcerative colitis.

In this Healio video, Aline Charabaty, MD clinical director of the Inflammatory Bowel Disease Center at Johns Hopkins, Sibley Memorial Hospital, discusses the underlying causes of ulcerative colitis.

In this Healio video, Aline Charabaty, MD clinical director of the Inflammatory Bowel Disease Center at Johns Hopkins, Sibley Memorial Hospital, discusses the underlying causes of ulcerative colitis.

The mission to understand rheumatoid arthritis inflammation at a molecular level has gained momentum with the rapid evolution of cutting-edge technologies, allowing researchers to delve deeper into the individual differences in inflammatory subtypes.

SAN DIEGO — A novel combination of elsubrutinib and upadacitinib, called ABBV-599, significantly improves systemic lupus erythematosus disease activity and flares through 48 weeks, according to data presented at ACR Convergence 2023.

VANCOUVER, British Columbia — Patients with ulcerative colitis were more likely to achieve clinical response and steroid-free clinical remission at 8 to 16 weeks on upadacitinib vs. ustekinumab, according to a presenter.

Rinvoq showed long-term efficacy and safety up to 140 weeks in the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and older, AbbVie announced in a press release.

Patients with moderate to severe ulcerative colitis achieved critical clinical, endoscopic and histological outcomes on maintenance doses of upadacitinib compared with placebo, with no new safety risks reported, according to study results.